- Position: Associate Professor (Clinical)
- Areas of expertise: psoriasis; pyoderma gangrenosum; neutrophilic dermatoses; chemokine biology; leukocyte-stromal interactions; clinical trials
- Email: K.Shams@leeds.ac.uk
- Location: Wellcome Trust Brenner Building, University of Leeds, St. James’s University Hospital, LS9 7TF
Dr Kave Shams is as Associate Clinical Professor and Honorary Consultant Dermatologist, with an interest in inflammation and chemokine biology, psoriasis and inflammatory skin disorders.
Dr Shams undertook his medical degree and an Honours degree in pharmacology at the University of Edinburgh. He subsequently underwent training in Internal Medicine and then Dermatology in Edinburgh and Glasgow. During this time, Dr Shams also undertook a PGCert in Translational Medicine at the University of Edinburgh, and was awarded a fellowship with the UK Translational Research Network for Dermatology.
Dr Shams completed his PhD titled the ‘Role and Regulation of the Atypical Chemokine Receptor ACKR2’ in the lab of Professor Gerard Graham, University of Glasgow, that is one of the most prominent chemokine research groups internationally. This work showed how focal skin inflammation communicates with remote unaffected skin to limit the wider spread of inflammation. The work in the Dr Shams’ group is focussed on translational psoriasis, neutrophilic dermatoses and skin inflammation research, with many excellent collaborative links within Leeds and further afield. A wide range of clinical-, in vivo- and in vitro- and molecular techniques are used, to better understand and treat inflammatory skin disease. The Leeds Centre for Dermatology has an excellent research infrastructure, large patient cohorts, and extensive experience in conducting patient-centred studies. The group is driven by the ambition to better treat skin disease and to better understanding the molecular basis for disease initiation. Dr Shams is a lead investigator of a range of national and international clinical trials, in addition to his laboratory based work.
Selected peer-reviewed papers (as of 2016)
§ K. Shams, G.J. Wilson, E. van den Bogaard, M.D. Singh, M.L. Le Brocq, S. Holmes, J. Schalkwijk, A.D. Burden, C.S. McKimmie, G.J. Graham. Spread of inflammation to remote tissues is restricted by the atypical chemokine receptor ACKR2. Journal of Investigative Dermatology. 2016 \n § E. Healy, S.J. Brown, S. Langan, S.G. Nicolls, K. Shams, N.J. Reynolds.
Identification of translational dermatology research priorities in the UK; results of an e-Delphi exercise. British Journal of Dermatology. 2015 Nov;173(5):1191-8 \n § M.D. Singh, V. King, H. Baldwin, A.D. Burden, A. Thorrat, S. Holmes, I.B. McInnes, R. Nicoll, K. Shams, K. Pallas, T. Jamieson, J.M. Carballido, A. Rot, G.J. Graham.
Involvement of chemokine-scavenging receptor D6 in the pathogenesis of psoriasis. American Journal of Pathology. 2012 Oct; 181(4): 1158–64. \n § K.L. Warburton, M.J. McPhee, L.J. Savage, A.E. Honan, R. Montgomery, M. Ghazavi, D. Torley, K. Shams, J. R. Ingram. Management of morphea: results of a national survey of UK clinicians. British Journal of Dermatology. 2014 Nov; 171(5): 1243–5. § K. Shams, G. Kavanagh.
Immediate reduction in sweat secretion with electrical current application in primary palmar hyperhidrosis. Archives of Dermatology (JAMA Dermatology). 2011 Feb; 147(2): 241–2. \n § G. Kavanagh, K. Shams. Botulinum toxin type A by iontophoresis for primary palmar hyperhidrosis. Journal of the American Academy of Dermatology. 2006 Nov; 55(5 Suppl): S115–17. \n § G. Kavanagh, C. Oh, K. Shams.
Botox® delivery by iontophoresis. British Journal of Dermatology. 2004 Nov; 151(5): 1093–5.
Book chapters, reviews
§ K. Shams, A.D. Burden. Updates from the Sixth International Congress ‘Psoriasis: From Gene to Clinic’, the Queen Elizabeth II Conference Centre, London, UK, 1–3 December 2011.
British Journal of Dermatology. 2012 Oct; 167(4): 757–61. \n § K. Shams, G. Grindlay, H.C. Williams.
What is new in atopic eczema? An analysis of systematic reviews published in 2009–2010.
Clinical and Experimental Dermatology. 2011 Aug; 36(6): 573–7.
§ K. Shams, B. Rzany. Hyperhidrosis. In: Evidence-Based Dermatology. 3rd Edition. Williams, Bigby, Herxheimer et al., editors. Wiley-Blackwell Publishers. 2014.
§ K. Shams, G. Gupta. Chapter 18: Management of field cancerization: actinic keratosis as an example. In: Clinical utility of molecular signature in cancer fields. G. Dakubo, editor. Nova Science Publishing. 2011.Psoriasis, chemokine, ACKR2, T cell, inflammation, skinLIRMM Staff
inflammatory skin diseases
patient-reported outcome measures
- MBChB with Honours (Edin.)
- BSc with Honours
- MRCP (UK) Dermatology
Research groups and institutes
- Leeds Institute of Rheumatic and Musculoskeletal Medicine
- Immunity and inflammation
- Musculoskeletal disease